Liraglutide and Semaglutide Market Report 2026

The liraglutide and semaglutide market size has grown rapidly in recent years. It will grow from $16.94 billion in 2025 to $18.88 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increasing prevalence of type 2 diabetes mellitus, limitations of traditional antidiabetic therapies, growing obesity rates, clinical success of injectable glp-1 drugs, rising awareness of cardiovascular risk reduction.

The liraglutide and semaglutide market size is expected to see rapid growth in the next few years. It will grow to $28.98 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to expanding obesity treatment indications, growing demand for convenient dosing options, increasing adoption of oral semaglutide, rising focus on comprehensive metabolic care, higher healthcare spending on chronic disease management. Major trends in the forecast period include rising adoption of glp-1 receptor agonists for diabetes care, growing use of glp-1 therapies in obesity management, increasing preference for once-weekly injectable treatments, expansion of oral glp-1 formulations, rising long-term use for glycemic and weight control.

The increasing prevalence of diabetes is expected to drive the growth of the liraglutide and semaglutide markets in the coming years. Diabetes is a chronic disease characterized by high blood sugar levels resulting from insulin resistance and inadequate insulin production in the body. The rise in diabetic patients is attributed to sedentary lifestyles, unhealthy dietary habits, and genetic factors. Liraglutide and semaglutide play a crucial role in managing diabetes by effectively controlling blood glucose levels and lowering the risk of diabetes-related complications. For example, in June 2024, the National Health Service (NHS), a UK government agency, reported that in 2023, over 549,000 additional individuals in England were identified as at risk of developing type 2 diabetes, increasing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This is a notable rise compared to 3,065,825 in 2022, marking an increase of nearly 20%. Consequently, the growing number of diabetic patients fuels the liraglutide and semaglutide markets.

Major companies in the liraglutide and semaglutide markets are focusing on developing anti-diabetic biosimilar drugs to improve glucose control and lower cardiovascular risks in diabetic patients. Anti-diabetic biosimilars are cost-effective, nearly identical versions of original diabetes biologics designed to provide the same therapeutic benefits as the original drugs. For example, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced a biosimilar of the widely used anti-diabetic drug Liraglutide for the first time in India. This biosimilar aims to enhance glycemic control in adults with type 2 diabetes mellitus. The launch reduces daily therapy costs, significantly widening access for more patients nationwide. With a price of around INR 100 for a standard 1.2 mg daily dose, it lowers therapy expenses by approximately 70% and requires a prescription for purchase.

In October 2023, Biocon Limited, an India-based biopharmaceutical company developing biosimilar versions of diabetes drugs liraglutide (Victoza) and semaglutide (Ozempic), formed a partnership with Juno Pharmaceuticals. The collaboration aims to bring Liraglutide, a complex drug-device combination for managing Type 2 diabetes and obesity, to market, covering regulatory approval, manufacturing, and supply. This initiative seeks to improve healthcare access and affordability through innovative treatments. Juno Pharmaceuticals, based in Canada, manufactures high-value generic medications, complex formulations, biosimilars, and other pharmaceutical products.

Major companies operating in the liraglutide and semaglutide market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Biocon Ltd., Glenmark Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, Hikma Pharmaceuticals Plc, Viatris Inc., Amneal Pharmaceuticals Inc., Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Limited.

North America was the largest region in the liraglutide and semaglutide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liraglutide and semaglutide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the liraglutide and semaglutide market by increasing costs associated with imported active pharmaceutical ingredients, injectable delivery devices, and specialized manufacturing inputs. These effects are more pronounced across liquid injectable formulations and branded products, particularly in regions such as asia-pacific and europe that rely on global pharmaceutical supply chains. Hospital and retail pharmacies face pricing pressure due to higher procurement costs. However, tariffs have also encouraged domestic manufacturing, expansion of generic development, and supply chain diversification, supporting long-term market resilience.

The liraglutide and semaglutide market research report is one of a series of new reports that provides liraglutide and semaglutide market statistics, including liraglutide and semaglutide industry global market size, regional shares, competitors with a liraglutide and semaglutide market share, detailed liraglutide and semaglutide market segments, market trends and opportunities, and any further data you may need to thrive in the liraglutide and semaglutide industry. This liraglutide and semaglutide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liraglutide and semaglutide are medications classified as glucagon-like peptide-1 (GLP-1) receptor agonists, mainly prescribed for the management of type 2 diabetes mellitus and used to enhance glycemic control in adults with this condition. They are administered via injection and are generally prescribed when other treatments for diabetes or obesity have not provided sufficient results. These medications are often included as part of a comprehensive treatment plan that incorporates diet, exercise, and other medications as required.

The primary forms of liraglutide and semaglutide are pills and liquids. Pills are medications formulated in solid form, usually taken orally to treat conditions such as type 2 diabetes mellitus and obesity. The various methods of administration include parenteral and oral routes, used for different applications such as type 2 diabetes mellitus and obesity. These medications are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The liraglutide and semaglutide markets consist of sales of medicines such as Victoza, saxenda, ozempic, and rybelsus. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.